- Home
- ADSE vs OMER Comparison
ADSE vs OMER Comparison
Compare ADSE & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADSE | OMER |
|---|---|---|
| Founded | 1980 | 1994 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 900.0M | 844.6M |
| IPO Year | 2021 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ADSE | OMER |
|---|---|---|
| Price | $11.28 | $20.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 15.6K | ★ 1.5M |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $549.86 | N/A |
| Revenue Next Year | N/A | $233.22 |
| P/E Ratio | ★ N/A | $26.94 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.20 | $4.06 |
| 52 Week High | $13.50 | $21.24 |
Technical Indicators
Market Signals| Indicator | ADSE | OMER |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 67.82 |
| Support Level | N/A | $18.00 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.82 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 89.35 |
Price Performance
Historical ComparisonAbout ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. The company generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.